Drug intelligence / Profile preview

fluperolone

Development stage: Unknown
Lead developer: Pfizer
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Topical

Overview

Fluperolone is a synthetic fluorinated prednisolone derivative classified as a corticosteroid. It is primarily used topically for its anti-inflammatory activity in the treatment of various dermatoses. As a member of the 20-oxosteroids class, it acts as an agonist of the glucocorticoid receptor, modulating gene expression to suppress inflammation and immune responses. Fluperolone is considered moderately potent among topical corticosteroids and has been marketed under names such as Methral.

Brand names: Methral
Other names: fluperolone acetate

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on fluperolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fluperolone.

Explore the full profile